|
PT1534335E
(pt)
*
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US7355008B2
(en)
*
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
AU2004273791A1
(en)
*
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
|
EP1747237A4
(en)
*
|
2004-04-16 |
2008-05-21 |
Macrogenics Inc |
SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
|
|
CA2565874C
(en)
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
WO2006028936A2
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
WO2006066078A2
(en)
*
|
2004-12-15 |
2006-06-22 |
Magrogenics, Inc. |
Fcϝriib-specific antibodies and methods of use thereof
|
|
CA2618068C
(en)
*
|
2005-08-05 |
2016-02-16 |
Amgen Inc. |
Stable aqueous protein or antibody pharmaceutical formulations and their preparation
|
|
DK2573114T3
(en)
*
|
2005-08-10 |
2016-07-04 |
Macrogenics Inc |
The identification and production of antibodies with variant Fc regions, and methods of using same
|
|
JP2009529331A
(ja)
*
|
2006-03-10 |
2009-08-20 |
マクロジェニクス，インコーポレーテッド |
変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
|
|
CA2660592C
(en)
|
2006-05-26 |
2016-07-12 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
EP1870422A1
(en)
*
|
2006-06-20 |
2007-12-26 |
SuppreMol GmbH |
Means for the treatment of diseases characterized by an excessive immune reaction
|
|
EP2032159B1
(en)
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
EP2029173B1
(en)
*
|
2006-06-26 |
2016-07-20 |
MacroGenics, Inc. |
Fc riib-specific antibodies and methods of use thereof
|
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
JP5220025B2
(ja)
|
2006-12-04 |
2013-06-26 |
プロメディオール， インコーポレイテッド |
線維症疾患を処置するための併用療法
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
US8497243B2
(en)
|
2007-07-06 |
2013-07-30 |
Promedior, Inc. |
Methods and compositions useful in the treatment of mucositis
|
|
US9884899B2
(en)
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
|
EP2234641B1
(en)
|
2008-01-03 |
2015-08-19 |
Genmab A/S |
Monoclonal antibodies against cd32b
|
|
CN106349390B
(zh)
|
2008-04-02 |
2019-12-10 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
|
SG189730A1
(en)
|
2008-04-02 |
2013-05-31 |
Macrogenics Inc |
Her2/neu-specific antibodies and methods of using same
|
|
WO2010033279A2
(en)
*
|
2008-06-04 |
2010-03-25 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
|
WO2009158696A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Zymogenetics, Inc. |
SOLUBLE HYBRID Fcγ RECEPTORS AND RELATED METHODS
|
|
EP2161031A1
(en)
*
|
2008-09-05 |
2010-03-10 |
SuppreMol GmbH |
Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
|
|
PT2405928T
(pt)
*
|
2009-03-11 |
2017-02-07 |
Promedior Inc |
Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
|
|
PT2405929T
(pt)
*
|
2009-03-11 |
2018-07-23 |
Promedior Inc |
Métodos de tratamento para distúrbios autoimunes
|
|
MX2011012047A
(es)
*
|
2009-05-13 |
2011-12-14 |
Genzyme Corp |
Inmunoglobulinas humanas anti-cd52.
|
|
UA110323C2
(en)
|
2009-06-04 |
2015-12-25 |
Promedior Inc |
Derivative of serum amyloid p and their receipt and application
|
|
HUE041034T2
(hu)
|
2009-06-17 |
2019-05-28 |
Promedior Inc |
SAP-variánsok és alkalmazásuk
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CN102712696A
(zh)
|
2009-09-16 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
|
MX2012004029A
(es)
|
2009-10-07 |
2012-05-08 |
Macrogenics Inc |
Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
|
|
DK2494356T3
(en)
*
|
2009-10-26 |
2017-05-15 |
Genentech Inc |
ASSAYS FOR THE DETECTION OF ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE OF ANAPHYLAXY
|
|
CA2781682A1
(en)
*
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
WO2011133886A2
(en)
*
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
US10017762B2
(en)
|
2010-11-24 |
2018-07-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for treating or preventing lupus
|
|
KR101813482B1
(ko)
*
|
2010-11-24 |
2017-12-29 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 |
루푸스의 치료 또는 예방을 위한 조성물 및 방법
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012142286A1
(en)
*
|
2011-04-12 |
2012-10-18 |
University Of Cincinnati |
Methods for suppressing allergic reactions
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
SI2766397T1
(sl)
|
2011-10-11 |
2018-09-28 |
F. Hoffmann-La Roche Ag |
Izboljšano sestavljanje bispecifičnih protiteles
|
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
|
EP2825197B1
(en)
|
2012-03-16 |
2018-06-06 |
Covagen AG |
Novel binding molecules with antitumoral activity
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
ES2597228T3
(es)
*
|
2012-06-27 |
2017-01-17 |
F. Hoffmann-La Roche Ag |
Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
|
|
KR20150052085A
(ko)
|
2012-09-14 |
2015-05-13 |
에프. 호프만-라 로슈 아게 |
2개 이상의 상이한 단위를 포함하는 분자의 제조 및 선별 방법, 및 이의 용도
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
PL3122781T3
(pl)
|
2014-03-28 |
2020-06-15 |
Xencor, Inc. |
Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
|
|
PL3140392T3
(pl)
|
2014-05-06 |
2023-11-27 |
F. Hoffmann-La Roche Ag |
Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
|
|
EA035269B1
(ru)
*
|
2014-08-13 |
2020-05-22 |
Зуппремоль Гмбх |
АНТИТЕЛО, НАПРАВЛЕННОЕ НА Fc-ГАММА-РЕЦЕПТОР IIB И Fc-ЭПСИЛОН-РЕЦЕПТОР
|
|
HK1245171A1
(zh)
|
2014-11-26 |
2018-08-24 |
Xencor, Inc. |
结合cd3和cd38的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
CN107636170A
(zh)
|
2015-02-04 |
2018-01-26 |
健泰科生物技术公司 |
突变型Smoothened及其使用方法
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
CN109069633A
(zh)
|
2016-04-15 |
2018-12-21 |
宏观基因有限公司 |
新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
EP3604340A4
(en)
|
2017-03-24 |
2021-01-06 |
Zenyaku Kogyo Co., Ltd |
ANTI-IGM / B-CELL SURFACE ANTIGEN-BISPECIFIC ANTIBODY
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
MX2020005651A
(es)
|
2017-11-30 |
2020-10-28 |
Novartis Ag |
Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
MX2021002165A
(es)
|
2018-08-23 |
2021-07-16 |
Regeneron Pharma |
Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
MX2021008561A
(es)
*
|
2019-01-23 |
2021-08-19 |
Genentech Inc |
Metodos de produccion de proteinas multimericas en celulas huesped eucariotas.
|
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2021006375A1
(ko)
*
|
2019-07-08 |
2021-01-14 |
(주)지아이이노베이션 |
Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물
|
|
AU2020358898B2
(en)
*
|
2019-10-01 |
2025-10-16 |
Epsilogen Ltd |
Hybrid antibody
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
KR20240116743A
(ko)
*
|
2021-11-09 |
2024-07-30 |
한양대학교 산학협력단 |
Fc 변이체를 포함하는 이종이합체 및 이의 제조방법
|
|
WO2023116770A1
(zh)
*
|
2021-12-22 |
2023-06-29 |
上海齐鲁制药研究中心有限公司 |
针对FcγRIIA的结合分子及其应用
|